

10/517010

DT15 Rec'd PCT/PTO 03 DEC 2004

"Express Mail" mailing label number	EV 392094384 US
Date of Deposit	Dec. 3, 2004
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Printed Name	QUEEN Thomas
Signature	

### PATENT APPLICATION

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Michael Joseph Coghlan, et al. )  
For : TRICYCLIC STEROID HORMONE )  
NUCLEAR RECEPTOR MODULATORS )  
National Stage of )  
International Application No.: PCT/US2003/016213 )  
Docket No. : X-15110 )

#### PRELIMINARY AMENDMENT ON FILING

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

#### Introductory Comments

In response to the International Search Report mailed 05 July 2004, Applicants submitted amendments to the original Claims (Claims 1-121) under Article 34 PCT for the purpose of obtaining a preliminary and non-binding opinion under the provisions of PCT Article 33. In those amendments, original claims 37-121 were cancelled and a new set of claims numbered 37-98 were added. Applicants now wish to further amend the claims with the present preliminary amendment. In order to alleviate any confusion over the claims being amended by this Preliminary Amendment, reference has been made to original Claims 1-121 as were filed with the PCT application. With the present Preliminary Amendment, Applicants now courteously request cancellation of original Claims 1-121, without prejudice to the filing of continuation applications for unclaimed subject matter; and entry of new Claims 122-137 before the beginning of examination on the merits.

Please amend the accompanying application as follows:

**Amendments to the specification** are reflected on page 3 of this paper.

**Amendments to the Claims** are reflected on page 4 of this paper.

**Remarks** begin on page 13 of this paper.